Shasun seeks shareholders nod for merger with Strides Arcolab

PTI New Delhi | Updated on January 24, 2018 Published on February 07, 2015

Shasun Pharmaceuticals is seeking shareholders’ approval for its proposed merger with Bangalore-based drug firm Strides Arcolab.

In a filing to the BSE, Shasun Pharmaceuticals said it is seeking shareholders nod for the merger scheme through a postal ballot.

Last year, the companies announced plans to merge, a move that will create an entity among the top 15 listed domestic drug makers with a turnover of over Rs 2,500 crore.

As part of the deal, Shasun will amalgamate with Strides in an all-stock transaction. Shashun shareholders will receive 5 equity shares of Strides for every 16 shares held by them in Shasun.

The combined entity would significantly enhance finished dosages portfolio in niche and complex domains with a pipeline of over 100 products and accelerates product filings with a combined R&D strength of over 400 personnel.

Strides, a Bangalore—based firm develops and manufactures IP—led niche pharmaceutical products. It has 8 manufacturing facilities presence in more than 75 countries.

Incorporated in 1976, Shasun is a global supplier of development and manufacturing services for intermediates, API (active pharmaceutical ingredients) and formulations to the pharmaceutical industry.

Published on February 07, 2015
This article is closed for comments.
Please Email the Editor